CTIS2023-507261-25-00进行中（未招募）1 期
A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-103, a Novel Formulation of UGN-102, for the Treatment of Patients With Low Grade (LG) Nonmuscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence (UTOPIA) - BL013
rogen Pharma Ltd.0 个研究点目标入组 67 人开始时间: 2024年5月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 67
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. Provide written informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol., 2. Patient must be = 18 years of age at the time of informed consent., 3. Patient who has LG NMIBC (Ta) histologically confirmed by cold cup biopsy at Screening or within 8 weeks before Screening. Note: This is a diagnostic biopsy to demonstrate histopathology of tumor and resection of the tumor is not to be performed. Residual tumor must be present and documented after biopsy and before instillation of study treatment., 4. History of at least 1 prior episode of NMIBC. Note: This refers to a previous episode(s) and not to the current episode for which the patient is being screened., 5. Has intermediate risk disease, defined as having 1 or 2 of the following: a. Presence of multiple tumors. b. Solitary tumor > 3 cm. c. Early or frequent recurrence (= 1 occurrence of LG NMIBC within 1 year of the current diagnosis at the initial Screening Visit) Note: Patients with all 3 factors are considered high risk and are not eligible to participate., 6. Negative voiding cytology for HG disease within 8 weeks before Screening, 7. Has adequate organ and bone marrow function as determined by routine laboratory tests as below: • Leukocytes = 3,000/µL (= 3 × 109/L). • Absolute neutrophil count = 1,500/µL (= 1.5 × 109/L). • Platelets = 100,000/µL (= 100 × 109/L). • Hemoglobin = 9.0 g/dL. • Total bilirubin = 1.5 × ULN. • AST and ALT = 2.5 × ULN. • ALP = 2.5 × ULN. • eGFR = 30 mL/min., 8. Has an anticipated life expectancy of at least the duration of the trial., 9. Both male and female patients: Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. a. Female partner of male patient: Willing to use 2 acceptable forms of effective contraception from enrollment through 6 months post treatment if the female partner is of childbearing potential (defined as premenopausal women who have not been sterilized). Acceptable methods of birth control which are considered to have a low failure rate (ie, less than 1% per year) when used consistently and correctly, such as implants, injectable, combined (estrogen/progesterone) oral contraceptives, intrauterine devices (only hormonal), condoms with spermicide, sexual abstinence* or vasectomized partner. * Sexual abstinence is defined as refraining from intercourse from enrollment through 6 months post treatment. Periodic abstinence (calendar, symptothermal, postovulation methods) is NOT an acceptable method of contraception. b. Female patient: Willing to use 2 acceptable forms of effective contraception from enrollment through 6 months post treatment if the patient is of childbearing potential (defined as premenopausal women who have not been sterilized)
排除标准
- •1. Received BCG treatment for UC within the previous 1 year., 10. Is pregnant or breastfeeding, 11. Has an underlying substance abuse or psychiatric disorder such that, in the opinion of the investigator, the patient would be unable to comply with the protocol, 12. History of prior treatment with an intravesical chemotherapeutic agent in the past 2 years except for a single dose of chemotherapy immediately after any previous TURBT, 13. Has participated in a study with an investigational agent or device within 30 days of enrollment, 14. Has previously participated in a study in which they received UGN-102, 15. Has any other active malignancy requiring treatment with systemic anticancer therapy (eg, chemotherapy, immunotherapy, radiation therapy). Superficial cancers such as cutaneous basal cell or squamous cell carcinomas that can be treated locally are allowed., 16. Has any other clinically significant medical or surgical condition that in the investigator’s opinion could compromise patient safety or the interpretation of study results, 17. Where applicable per country regulation, the patient must not be currently committed to an institution by virtue of an order issued by either judicial or administrative authorities, 2. History of HG bladder cancer (papillary or CIS) in the past 2 years, 3. Known allergy or sensitivity to any component of the study treatment (including excipients) that in the investigator’s opinion cannot be readily managed, 4. Clinically significant urethral stricture that would preclude passage of a urethral catheter, 5. History of: a. Neurogenic bladder. b. Active urinary retention. c. Any other condition that would prohibit normal voiding, 6. Past or current muscle invasive bladder cancer (ie, T2, T3, T4) or metastatic UC, 7. Current tumor staging of T1, 8. Concurrent UTUC, 9. Evidence of active UTI that in the investigator’s opinion cannot be treated and resolved prior to biopsy and/or administration of study treatment
研究者
相似试验
进行中（未招募）
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder Canceron-Muscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005948-29-BGroGen Pharma Ltd.220
招募中
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder Canceron-Muscle Invasive Bladder CancerMedDRA version: 20.0Level: PTClassification code 10005003Term: Bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2021-005948-29-LTroGen Pharma Ltd.220
招募中
1 期
An Open Study of the Efficacy and Safety of a new drug in Patients with Bladder CancerEUCTR2021-005948-29-ATroGen Pharma Ltd.220
招募中
1 期
A Phase III multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythaemia patientsEssential ThrombocythaemiaMedDRA version: 21.0Level: PTClassification code: 10015493Term: Essential thrombocythaemia Class: 100000004864MedDRA version: 23.0Level: LLTClassification code: 10043549Term: Thrombocythaemia Class: 10005329CTIS2023-505160-12-00Aop Orphan Pharmaceuticals GmbH129
进行中（未招募）
不适用
A phase III, single arm, multicentre study to evaluate the efficacy and safety of a subcutaneous four-month sustained-release formulation of triptorelin, a gonadotrophin releasing hormone analogue in patients with prostate cancer - Not applicableEUCTR2006-001511-30-LVBeafour Ipsen Pharma100